Heartseed, Inc. (JP:219A)
:219A
Want to see JP:219A full AI Analyst Report?
Top Page
Heartseed, Inc.
(219A)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥1,842.00
▲(2.11% Upside)
Action:Reiterated
Date:02/19/26
The score is driven primarily by the FY2025 financial turnaround (profitability and positive free cash flow) and a strong, low-leverage balance sheet. This is tempered by the prior multi-year loss/cash-burn history and an expensive valuation (high P/E), while technicals are neutral-to-modestly supportive but still below the 200-day trend.
Positive Factors
Conservative Balance Sheet
Very low leverage and a large equity base provide durable financial flexibility, reducing insolvency risk and enabling the firm to fund clinical programs or partnerships without needing frequent high-cost debt. This strengthens long-term resilience through funding cycles and shocks.
Negative Factors
Historic Multi-Year Losses
A recent multi-year history of steep losses and cash burn demonstrates execution and commercialization risk; earnings have been volatile. If growth or cash generation falters, the company may revert to funding dependence or dilution, undermining long-term capital efficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage and a large equity base provide durable financial flexibility, reducing insolvency risk and enabling the firm to fund clinical programs or partnerships without needing frequent high-cost debt. This strengthens long-term resilience through funding cycles and shocks.
Read all positive factors
Heartseed, Inc. (219A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥40.78B
Dividend YieldN/A
Average Volume (3M)738.74K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees39
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,874,200
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Heartseed, Inc. Business Overview & Revenue Model
Company Description
Heartseed, Inc. engages in the provision of cardiac regenerative medicine. The company was founded by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa and Yutaro Kasai on November 30, 2015 and is headquartered in Tokyo, Japan....
How the Company Makes Money
Heartseed, Inc. generates revenue through partnerships with pharmaceutical and biotech companies, offering licensing agreements for its proprietary technologies and products under development. Additional income sources include research and develop...
Heartseed, Inc. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 3.03B | 873.61M | 344.73M | 499.06M |
| Gross Profit | 3.03B | 0.00 | 0.00 | 0.00 |
| EBITDA | 278.71M | -996.98M | -1.45B | -1.46B |
| Net Income | 163.38M | -812.73M | -1.47B | -1.41B |
Balance Sheet | ||||
| Total Assets | 8.14B | 7.07B | 5.72B | 4.94B |
| Cash, Cash Equivalents and Short-Term Investments | 7.34B | 5.30B | 4.59B | 3.99B |
| Total Debt | 890.00K | 5.39M | 11.58M | 30.98M |
| Total Liabilities | 571.35M | 444.34M | 450.19M | 208.45M |
| Stockholders Equity | 7.57B | 6.62B | 5.27B | 4.73B |
Cash Flow | ||||
| Free Cash Flow | 1.05B | -1.36B | -1.13B | -1.92B |
| Operating Cash Flow | 1.08B | -1.34B | -797.93M | -1.92B |
| Investing Cash Flow | 72.64M | -67.13M | -425.69M | -994.00K |
| Financing Cash Flow | 375.76M | 2.12B | 1.85B | -22.16M |
Heartseed, Inc. Technical Analysis
Positive
1804.00
Price Trends
1878.74
Positive
1880.40
Positive
2366.16
Negative
Market Momentum
17.21
Negative
55.37
Neutral
63.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:219A, the sentiment is Positive. The current price of 1804 is below the 20-day moving average (MA) of 1829.60, below the 50-day MA of 1878.74, and below the 200-day MA of 2366.16, indicating a neutral trend. The MACD of 17.21 indicates Negative momentum. The RSI at 55.37 is Neutral, neither overbought nor oversold. The STOCH value of 63.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:219A.
Heartseed, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥41.35B | 19.61 | ― | 2.53% | 1.74% | 41.32% | |
63 Neutral | ¥40.78B | ― | ― | ― | ― | ― | |
60 Neutral | ¥499.01B | 16.97 | ― | 0.93% | 6.74% | 6.60% | |
54 Neutral | ¥14.64B | 14.74 | ― | 2.32% | 8.01% | -15.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥8.94B | -8.87 | ― | ― | ― | 32.31% | |
48 Neutral | ¥6.19B | -12.09 | ― | 2.65% | 11.78% | 86.75% |
* Healthcare Sector Average
JP:219A
Heartseed, Inc.
1,783.00
-647.00
-26.63%
JP:2796
Pharmarise Holdings Corp.
527.00
50.92
10.70%
JP:3349
COSMOS Pharmaceutical Corporation
6,269.00
-2,744.15
-30.45%
JP:4350
Medical System Network Co., Ltd.
485.00
56.18
13.10%
JP:4931
Shinnihonseiyaku Co., Ltd.
1,932.00
-251.01
-11.50%
JP:190A
Chordia Therapeutics Inc.
117.00
-108.00
-48.00%
Heartseed, Inc. Corporate Events
Heartseed Narrows Quarterly Loss but Projects Deeper Full-Year Deficit
May 15, 2026
Heartseed Inc. reported non-consolidated net sales of ¥465 million for the three months ended March 31, 2026, with an operating loss of ¥75 million and a net loss of ¥58 million, narrowing per-share losses to ¥2.54. The company...
Heartseed launches post-delivery RSU plan to align board pay with shareholder value
Apr 16, 2026
Heartseed Inc. has approved the grant of post-delivery restricted stock units to three board directors, excluding independent and non-executive members, under a stock-based compensation plan authorized at its recent shareholder meeting. The initia...
Heartseed revamps governance with new executive officer system and board changes
Feb 25, 2026
Heartseed Inc. announced it will introduce an executive officer system from March 27, 2026, to strengthen corporate governance and create a more agile management structure. Under the new framework, the Board of Directors will concentrate on strate...
Heartseed Issues Cautionary Notice Alongside FY2025 Financial Results
Feb 16, 2026
Heartseed Inc. has released an informational document presenting its financial results for the fiscal year ended December 31, 2025, emphasizing that the materials are for informational purposes only and may be subject to change without notice. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.